Text Size

Prediction of Acute Rejection in Renal Transplant

This study has been completed.
Sponsor:
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00205257
First received: September 13, 2005
Last updated: February 25, 2009
Last verified: February 2009
History of Changes

September 13, 2005
February 25, 2009
September 2001
February 2007   (final data collection date for primary outcome measure)
kidney biopsy pathology [ Time Frame: 1 year ] [ Designated as safety issue: No ]
kidney biopsy pathology
Complete list of historical versions of study NCT00205257 on ClinicalTrials.gov Archive Site
urinary chemokines [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Prediction of Acute Rejection in Renal Transplant
Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant

Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Kidney Transplant
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
February 2007
February 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • One hundred subjects undergoing kidney biopsy for suspected rejection
  • Forty subjects that have stable graft function with normal level of blood creatinine (No biopsy is needed at the time of sample collection).

Exclusion Criteria:

  • Subjects under the age of 18
  • Gender of potential subjects male or female
  • Age Limits greater than 18 years of age
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00205257
2001-252
Not Provided
Not Provided
University of Wisconsin, Madison
Not Provided
Principal Investigator: Thomas Chin University of Wisconsin Medical School
University of Wisconsin, Madison
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP